COVID-19 coagulopathy vs disseminated intravascular coagulation.Blood Adv. 2020 06 23; 4(12):2850.BA
Links
MeSH
BetacoronavirusCOVID-19Coronavirus InfectionsDiagnosis, DifferentialDisseminated Intravascular CoagulationEndothelium, VascularFibrin Fibrinogen Degradation ProductsHumansPandemicsPneumonia, ViralProthrombin TimePulmonary EmbolismRespiratory Distress SyndromeSARS-CoV-2ThrombocytopeniaThrombophiliaThrombotic Microangiopathies
Pub Type(s)
Address
Journal Article
Language
eng
PubMed ID
32574369
Citation
Levi, Marcel. "COVID-19 Coagulopathy Vs Disseminated Intravascular Coagulation." Blood Advances, vol. 4, no. 12, 2020, p. 2850.
Levi M. COVID-19 coagulopathy vs disseminated intravascular coagulation. Blood Adv. 2020;4(12):2850.
Levi, M. (2020). COVID-19 coagulopathy vs disseminated intravascular coagulation. Blood Advances, 4(12), 2850. https://doi.org/10.1182/bloodadvances.2020002197
Levi M. COVID-19 Coagulopathy Vs Disseminated Intravascular Coagulation. Blood Adv. 2020 06 23;4(12):2850. PubMed PMID: 32574369.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - COVID-19 coagulopathy vs disseminated intravascular coagulation.
A1 - Levi,Marcel,
PY - 2020/05/01/received
PY - 2020/05/19/accepted
PY - 2020/6/24/entrez
PY - 2020/6/24/pubmed
PY - 2020/7/7/medline
SP - 2850
EP - 2850
JF - Blood advances
JO - Blood Adv
VL - 4
IS - 12
SN - 2473-9537
UR - https://www.unboundmedicine.com/medline/citation/32574369/COVID_19_coagulopathy_vs_disseminated_intravascular_coagulation_
DB - PRIME
DP - Unbound Medicine
ER -